Revvity, Inc.

NYSE:RVTY

Medical - Diagnostics & Research

Healthcare
$152.43 -3.36%

-$3.40 today

Market cap
$17.02B
Beta
1.11
P/E (TTM)
45.4
EPS (TTM)
$2.15
Dividend yield
0.29%
52W Low $81.22High $118.30

Volume 1.09M

Average 1.27M

RVTY EBITDA Margin

EBITDA as a percentage of revenue.

Revvity, Inc.NYSE: RVTY

EBITDA Margin · Q2 FY2026 · quarter ended Jul 2026

EBITDA Margin narrows to 25.8%

EBITDA Margin was 25.8% in Q2 FY2026, down 1.1 pp from a year earlier. On a trailing-twelve-month basis it was 26.3%, down 3.0 pp year over year. Over 3 fiscal years it narrowed by 8.9 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 13 analysts of 45.9% for the fiscal year ending Dec 2026, up from 26.8% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJul 2026
25.8%+0.6 pp QoQ
Last fiscal yearDec 2025
26.8%-3.7 pp YoY
LTMJul 2026
26.3%-3.0 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.1 pp+21.9 pp+23.0 pp
1 year-3.7 pp+19.1 pp+22.7 pp
3 years-8.9 pp+16.8 pp+25.7 pp
5 years+16.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
26.8%
Year-over-year change
-3.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How RVTY compares with its peers on the latest reported figures

  • RVTY's LTM Jul 2026 EBITDA Margin of 26.3% is the 6th highest of the 11 companies compared; the peer median is 25.3%.
  • Its year-over-year change of -3.0 pp is the 8th highest of 11, against a peer median of -1.1 pp.
  • Over three fiscal years its change of -8.9 pp compares with a peer median of -2.2 pp.
RVTY Competitors Peer median
EBITDA Margin for RVTY and competitors
Company Period LTM level YoY 3-year change
QGENQiagen N.V.LTM Jun 202633.5% -1.6 pp-2.1 pp
MTDMettler-Toledo International Inc.LTM Jun 202631.6% +0.0 pp-0.7 pp
DHRDanaher CorporationLTM Sep 202627.7% -0.6 pp-7.3 pp
AAgilent Technologies, Inc.LTM Jul 202627.6% +1.1 pp-1.4 pp
TECHBio-Techne CorporationLTM Sep 202626.8% +8.6 pp-11.9 pp
RVTYRevvity, Inc.LTM Jul 202626.3% -3.0 pp-8.9 pp
TMOThermo Fisher Scientific Inc.LTM Sep 202623.7% -2.2 pp-0.9 pp
WATWaters CorporationLTM Jul 202620.5% -14.2 pp-2.3 pp
BIOBio-Rad Laboratories, Inc.LTM Jun 202619.9% -6.2 pp+208.5 pp
MLABMesa Laboratories, Inc.LTM Mar 202617.4% +0.1 pp-3.0 pp
CRLCharles River Laboratories International, Inc.LTM Jun 20265.5% -7.6 pp-14.6 pp
Peer median (excluding RVTY) 25.3%-1.1 pp-2.2 pp

Competitors are the stored peer set for RVTY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.83B3.31B2.75B2.76B2.86B
Cost of Revenue1.55B1.55B1.43B1.43B1.34B
Gross Profit2.28B1.76B1.32B1.32B1.52B
Gross Margin59.6%53.2%48.1%48.0%53.1%
Research & Development200.34M221.62M216.58M196.84M215.84M
Selling, General & Admin741.61M757.99M706.12M715.3M945.29M
Operating Expenses941.95M979.61M922.7M912.14M1.16B
Depreciation & Amortization311.44M427M431.77M427.85M405.34M
EBITDA1.62B1.18B713.56M840.25M765.8M
EBITDA Margin42.2%35.7%25.9%30.5%26.8%
Operating Income1.34B781.12M399.49M410.52M356.64M
Operating Margin35.0%23.6%14.5%14.9%12.5%
Interest Income2.24M3.59M72.13M73.19M31.1M
Interest Expense102.13M103.96M98.81M96.28M92.19M
Other Income / Expenses(136.42M)(129.29M)(216.52M)(94.39M)(88.36M)
Income Before Tax1.2B651.84M182.98M316.13M268.28M
Pre-Tax Margin31.4%19.7%6.7%11.5%9.4%
Income Tax Expense314.15M139.16M3.47M33.06M25.8M
Net Income943.16M569.18M(118.38M)295.83M241.68M
Net Margin24.6%17.2%-4.3%10.7%8.5%
EPS (Basic)8.124.51(0.95)2.412.08
EPS (Diluted)8.084.50(0.95)2.412.08
Weighted Avg Shares116.17M126.16M124.7M122.76M113.21M
Weighted Avg Shares (Diluted)116.67M126.43M124.81M122.82M113.21M

Revvity, Inc.

NYSE:RVTY

Intrinsic Alpha fair value

Locked

Current Price

$152.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.